is semaglutide a glp 1 drug Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment GLP-1s for Weight Loss: What

doi: 10.1007/s12311-009-0105-9 130 Sajdel-SulkowskaEMXuMMcGinnisWKoibuchiN

Before and After Results Clinical trials have shown: 1015% average body weight reduction with semaglutide (dose-dependent) Up to 1522% average weight reduction in some tirzepatide trials Timeline Expectations: Appetite changes: 14 weeks Visible weight loss: 48 weeks Significant results: 36 months Individual results vary based on dose, adherence, diet, activity level, and metabolic health

If you experience redness, itching, or irritation, discontinue use immediately and consult a dermatologist

Novo Nordisk offers the Novo Nordisk Patient Assistance Program (PAP) for people with Type 2 diabetesone of the weight-related conditions Wegovy is approved for in patients with a BMI of 27 or higher